ST. LOUIS--(BUSINESS WIRE)--Antegrin Therapeutics, a drug discovery and development company focused on novel treatments for fibrotic diseases, announced today the publication of key preclinical data in the current online issue of Nature Medicine. The research highlights the role played by multiple specific av integrins in activating the central mediator of fibrosis, transforming growth factor beta (TGFß). The paper also reports positive findings in animal models of lung and liver fibrosis resulting from pharmacologic inhibition of these integrins.
Help employers find you! Check out all the jobs and post your resume.
